Clinical Observation On Professor Fu Bin’s Treatment Of Chronic Kidney Disease Stage 2-4 With The Method Of Harmony

Purpose:The purpose of this project is to expand the idea of enriching the treatment of CKD by evaluating clinical efficacy and exploring the therapeutic effect by observing and analyzing the clinical indicators and changes in the renal function of patients with chronic kidney disease stage 2-4(CKD 2-4)by Professor Fu Bin using harmony therapy.Method:A clinical retrospective case-control study was used to collect information on CKD 2-4non-dialysis treatment cases from December 1,2016 to December 1,2020,in the outpatient and wards of the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine that met the inclusion and exclusion criteria: Name,gender,age,date of visit,primary kidney disease,Scr,BUN,ALB,potassium,HGB,clinical symptoms and prescription information of Chinese medicine taken by Professor Fu and the harmony therapy prescription.According to whether to use the harmony therapy prescription,the cases were divided into observation group(harmony therapy prescription + conventional western medicine treatment)and control group(conventional western medicine treatment).The observation group and the control group were matched with 1:1 propensity score matching(PSM),and the caliper value was set to 0.05 to control the differences in factors such as age,gender,primary kidney disease,and biochemical indicators before treatment.Observation group(n=49),control group(n=49).Use SPSS 25.0 software to count,test and analyze the data,observe the overall changes in clinical indicators and syndrome scores of the two groups before and after treatment,as well as the second and third phases,so as to evaluate the improvement of CKD 2-4 patients by Professor Fu’s use of harmony therapy prescription.Result:1.Case distribution: A total of 127 patients with chronic kidney disease who met the research criteria were collected in this study.After PSM,a total of 98 patients were included.There were 49 people in the observation group and 49 people in the control group.Among them,63 were males,accounting for about 64.29% of the total,and 35 were females,accounting for about 35.71% of the total.The gender ratio of patients was 1.8:1;In terms of age,the youngest was 24 years old,and the oldest was 74 years old.the average age is55.82±11.04 years old;In terms of primary kidney disease,34 cases of diabetic nephropathy(DN),accounting for about 34.69%,5 cases of polycystic kidney disease(PKD),accounting for about 5.10%,7 cases of chronic nephritis,accounting for about 7.14%,ANCA nephritis 3cases,accounting for about 3.06%,19 cases of hypertension and renal damage,accounting for19.39%,13 cases of nephrotic syndrome,accounting for about 13.27%,5 cases of lupus nephritis(LN),accounting for about 5.10%,hyperuricemia nephropathy 5 cases,accounting for about 5.10%,1 case of kidney stones,accounting for 1.02%,6 cases of unexplained renal damage,accounting for about 6.12%;Among the included cases,42 cases of CKD stage 2,accounting for about 42.86%,and 45 cases of CKD stage 3.,Accounting for about 45.92%,11 cases of CKD stage 4,accounting for about 11.22%.2.Baseline situation: There was no statistical difference between the two groups in terms of gender,age,primary kidney disease,CKD distribution and other general data,as well as clinical indicators such as Scr,BUN,eGFR,ALB,potassium,and HGB,and TCM syndrome scores.,Comparable.3.Efficacy:3.1 Clinical indicators: After treatment,Scr,BUN,eGFR,ALB,HGB,and syndrome scores all improved compared with before,and there was no obvious trend of potassium change.(1)CKD 2-4 stage: After treatment,the scores of syndromes between the two groups(P=0.046)are statistically different,and the observation group is better than the control group;Scr(P=0.206),BUN(P=0.418),eGFR(P=0.201)),ALB(P=0.720),potassium(P=0.420),HGB(P=0.075),there was no statistical difference.(2)CKD stage 2: After treatment,there are(significant)statistical differences in Scr(P=0.048)and potassium(P=0.008)between the two groups.The observation group(significantly)is better than the control group;BUN(P=0.099),eGFR(P =0.119),ALB(P=0.252),HGB(P=0.084),TCM syndrome score(P=0.888),there was no statistical difference.(3)CKD stage 3: After treatment,potassium(P=0.032)was statistically different between the two groups,and the observation group was better than the control group;Scr(P=0.171),BUN(P=0.495),eGFR(P=0.069),ALB(P=0.690),HGB(P=0.452),TCM syndrome score(P=0.140),there was no statistical difference.3.2 Clinical efficacy: After treatment,the clinical efficacy of the two groups was statistically different in CKD 2-4(P=0.019)and CKD 2(P=0.028),the observation group was better than the control group;CKD 3(P=0.286)had no statistical difference,But the total effective rate of the observation group is higher than that of the control group.3.3 The efficacy of the evidence: After treatment,there was a statistically significant difference in the efficacy of CKD 2-4(P=0.041)between the two groups,and the observation group was better than the control group;CKD 2(P=0.870)and CKD 3(P=0.070)were not statistically different Difference,but the total effective rate of the observation group is higher than that of the control group.3.4 Clinical symptoms: After treatment,the two groups had statistical differences in burnout,limb drowsiness,dizziness,lumbar acid,low back pain,abdominal fullness,low intake,edema,stickiness in the mouth,dry mouth,frequent night urine,false stool,stool dry knot symptoms(P<0.0 05),the observation group improved joint pain(P=0.014),cold-flung limb cold(P=0.020),skin armor error(P=0.025),and the control group had statistical significance in improving 24 h urine(P=0.014)symptoms.Comparison between groups: The differences between the two groups in improving burnout fatigue(P=0.000),abdominal fullness(P=0.003),edema(P=0.000),and night urine frequency(P=0.006)were statistically significant.In conclusion:1.Harmony therapy can delay the progression of CKD 2-4 stages,reduce Scr,and effectively stabilize kidney function.2.Harmony therapy prescription can significantly improve the clinical symptoms of patients,especially in improving fatigue,abdominal distension and edema.3.Harmony therapy prescription has more prominent effect on CKD stage 2.